Member Info for ParanoiaBlue

Thanks for that. It also continues: "We believe that, with a number of products now in late-stage development, we are primed to make the transition from being a development company to being a company that both develops and commercialises novel cancer drugs,” said the group. With 7 strong, and 1 buy, recommendations – this one has just got to fly at some stage. The SP has been dodging around this lower level for ages. ATB

18/11/08 Broker - Seymour Pierce - Buy [Reiteration]

...to the week. Heading back towards break-even :)

...start to a new week, yet again!

Thankfully, another good trading day. I’ve also been somewhat sceptical of charts/charting etc – to put it politely. No offence meant! If it helps you – ATB. PS I hope that they are wrong, if they predict any SP drop in the near future!

I note this from their website. It has the potential to confuse – it certainly was the case for me when I first scanned it. It is dated the 13th but the conference is actually on the 18th!! “London, UK and Cambridge, MA: 13 November 2008 - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Director of Communications, Dr Daniel Elger, will be presenting at the Lazard Capital Markets healthcare conference in New York. The presentation is scheduled for 14:40 EST (19:40 GMT) on Tuesday, November 18th. A webcast of the presentation will be available to all on Antisoma's website at www.antisoma.com. For live viewing of the webcast, it is recommended that viewers log on 15 minutes early in order to register and download any necessary software.” That is the same day as their AGM, as far as I can see. So this conference is giving them exposure in the States.

‘Zinc miner Griffin Mining announced the purchase of a 39% stake in AIM-listed Spitfire Oil for 2.5 million pounds. Spitfire is evaluating the Salmon Gums lignite deposit in Western Australia as a possible source of fuel oil and distillate. Griffin's chairman and FD are both already on the board, and the purchase has been made to diverse Griffin's commodity and geographical risk. "The purchase does little damage to the company's cash pile (84 million dollars at 30 June) and we retain our recommendation. BUY," commented broker Seymour Pierce. Griffin shares dropped 1.25p to 18.5p.’

Eric Dodd 50,000 @ 20.50p = £10,250.00 [11-Nov-08] Ah! Pharmas getting more healthy - hopefully, also more financially, as well !!

You are more “bluer” than I!! There is still potential, here. In fact, pharmas have been holding their own, in the recent turmoil. [Check out PTI [BTG] & ASM for instance] Hold the faith. PS The way that things are panning out – the pharmaceutical industry may well be the best place to hover around !! ATB PPS Check their website – OK, I know that all of the such, spin massively – but I’ve seen through much more obvious facades! At least hold for now!

BTG's shares have soared by 34.5 per cent in the past month, which chief executive, Louise Makin, says proves that investors see the company differently to the rest of the sector. There is probably more than a degree of truth in that, especially as most other biotech groups have struggled to attract buyers in the same period. The biggest, if unlikely, risk, warns Dr Makin, is not achieving the successful integration of Protherics, an immunotherapeutic group BTG has acquired for £218m. If merged well, the combined company will have an impressive pipeline of deals, with some suggesting a share price of £3 should not be out of the question. A punt on any biotech firm is a risky investment, but those wanting exposure to the sector could do worse than buy BTG. With £67.5m of cash on the balance sheet and an ambition to hit the FTSE 250, investors could do very nicely. Buy.

Biotech and life science groups are traditionally not the type of companies investors should be buying in a downturn. In good times, such groups can raise money with abandon, pumping more and more into research without ever really having to worry too much about turning good science into profitable drugs. In bad times, however, the sector can become a graveyard of good ideas as investors get more nervous about groups that are great at developing, but not proficient at making profits. BTG, with good reason, sees itself a different kettle of fish. The good news for investors is it is profitable: yesterday's interim results showed the firm, which specialises in neuroscience treatments, returned a pre-tax profit of £3.4m in the six months to the end of September, which comes largely from licensing deals. While the profit figure was down on the same period last year, it is the recurring royalty revenues from these licensing deals, which jumped by 17 per cent to £24.2m, that the group says is salient.

“Life sciences focused BTG published a buoyant set of interim figures for the six months ended 30 September. Net recurring royalty revenues came in 25% higher at 15.1 million pounds compared to the first half of 2007-8. That gave the firm 3.4 million pounds in pre-tax profits against 15.2 million pounds, comparing the same periods. At the half year stage, BTG also reported that it was sitting on 57.5 million pounds cash. On that note, Louise Makin, CEO, commented: “With a robust cash position and the merger with Protherics due to complete in December, BTG is well positioned.” Apart from the company’s recommended offer for Protherics, the business also said that had made good progress with its internal development programmes. The shares added 1.25p to 152.5p. Tom Winnifrith of t1ps.com has tipped this stock as a ‘speculative buy’ at under 100p and is still bullish, noting the company’s recurring royalties figures as evidence of its progress.”

Demonstration at Chinese Grand Prix launches marketing programme The successful launch of the first model of Antonov’s six speed automatic transmission (the TX6) at the Chinese Chengdu A1 Grand Prix on Sunday 9th November 2008 marks the start of a period of demonstrations to numerous car makers across China. At the Chinese Grand Prix, a number of senior industry contacts including government representatives were able to assess the new six speed automatic transmission fitted to a 1.6l VW Golf demonstration vehicle. Over the coming weeks Antonov will be meeting with a variety of Chinese vehicle manufacturers with demonstrations, technical and commercial discussions all taking place to promote Antonov’s technology for inclusion in their mid-range vehicle production programmes. CEO John Moore commented: “This is an important milestone for the company as it represents the first time a production ready Antonov automatic transmission within a demonstration vehicle has been marketed to potential Chinese automotive clients. We have already successfully demonstrated the vehicle in Europe and now have underpinned this progress by enabling Chinese domestic car brands to assess Antonov’s six speed automatic transmission directly. I look forward to reporting further updates in due course.” The Phoenix rises…. Hmmmmm….

UBS upgraded its rating on bus and rail group Stagecoach to 'neutral' from 'sell', prompted by the recent fall in its share price. Stagecoach is now trading on an earnings multiple of 8.6, compared with a sector average of 8.2, making the company look less expensive versus its peers than in the past, argued the Swiss bank. However, UBS warned the outlook remains uncertain, with UK rail revenue growth slowing down. "We believe this trend will accelerate in the next six months, as job losses and economic slowdown have their effect," said UBS, which is currently forecasting rail volumes to decline by 2% next year for all UK companies, with Stagecoach suffering more than most. Its 12-month price target has been trimmed from 218p to 210p based on a sum of the parts valuation. "Stagecoach remains one of the best companies in terms of operations and financial returns in our view. However, we cannot overlook the fact it is highly geared into volumes," concluded UBS. Stagecoach shares finished 7.5p behind the start line at 193p.

Some good upside in the SP. Almost In positive territory, but think I’m going hold, at least until, I see how the up- and-coming AGM pans out

PTI rising well being sucked along in the BTG slipstream!

...on the back of the recent good news.

RNS Number : 6176H Cyprotex PLC (LSE:CRX), the drug discovery services and information group, announces a trading update on its performance-to-date in calendar year to 2008. Progress for the ten months to the end of October has been encouraging. The group produced a net profit in both the second and third quarters of 2008, and the Directors expect the same positive trend to continue into the fourth quarter. As a result the Directors expect 2008 full year net profits (including significant adjustments for non-recurring costs associated with the recent board restructuring) to be in excess of the current market expectations. The Company announces that it will hold an investor call on 11th November 2008 at 16.30 (GMT). The call can be accessed by dialing into conference call telephone number: 0800-358-8171 and following the instructions to input pass code number: 329475 followed by #. A presentation to accompany and support the call has been updated and will be available on the Company's website: www.cyprotex.com on the morning of the conference call.

..over 12% on the coat-tails of BTG

I wonder if there will be any concrete results, forthcoming, re: early September market chatter about rumours of a takeover. That’s been a couple of months now.